About this trial

This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.

Eligibility criteria

Qualifiers

Individuals with a severely painful and/or disabling hip joint with osteoarthritis, traumatic arthritis or developmental dysplasia of the hip or avascular necrosis of the femoral head.

In order to take part in this study, all study participants must be between the ages of 18 and 75 years of age, at the time of surgery.

Scheduled for a primary total hip replacement.

Disqualifiers

Active infection

Pregnancy

Mental illness where the known condition is likely to compromise the patient's ability to consent, affect the patient's assessment of their progress or complete the 10 year cycle of follow-up appointments and reviews

Grossly distorted anatomy (surgeon's discretion)

Trial design

Treatments tested in this trial

  • SMS femoral stem

Treatment groups

No treatment groups listed

Locations

4
Austria
Herz-Jesu Krankenhaus1030, Vienna Austria
Italy
Istituto Ortopedico Galezzi20161, MilanMilan, Italy
Switzerland
Bürgerspital SolothurnCH-4500, Solothurn Switzerland
United Kingdom
The Elective Orthopaedic Centre (EOC)KT18 7EG, EpsomSurrey, United Kingdom

Sponsors and collaborators

Medacta International SA

Lead sponsor